HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Further characterization of skin tumor promotion and progression by mezerein in SENCAR mice.

Abstract
This study evaluated the skin tumor-promoting activity of mezerein in SENCAR mice. The effect of initiation dose of 7,12-dimethylbenz(a)anthracene (DMBA) on tumor promotion by mezerein was examined. Excellent dose-response relationships were observed for initiation with DMBA at 0.2-20 micrograms per mouse with mezerein as a complete promoter. None of the mezerein-only promotion groups had papilloma responses similar to those of the corresponding groups receiving two-stage promotion with 12-O-tetradecanoylphorbol-13-acetate (TPA) followed by mezerein, even when a 40-micrograms initiating dose of DMBA was used. The effect delaying promotion with mezerein for 10 weeks was also examined in mice initiated with either 0.2, 2, 20, or 40 micrograms of DMBA per mouse. The 10-week delay led to a slight increase in the number of papillomas per mouse in some but not all treatment groups. Again, none of the delayed-mezerein-treatment groups had papilloma responses similar to those of the corresponding two-stage promotion (TPA-mezerein) groups at any corresponding initiating dose of DMBA. Finally, the progression of papillomas to carcinomas during promotion with mezerein was examined in groups of mice initiated with either 2 or 20 micrograms of DMBA. Higher ratios of carcinomas to papillomas were observed in mice promoted with mezerein than in mice receiving TPA promotion or two-stage promotion (TPA-mezerein). However, the presence of two to four times more papillomas in some mezerein-treated groups did not lead to greater numbers of carcinomas than in the groups with fewer papillomas. The data do not support the idea that spontaneous stage I promotion can be induced by delaying mezerein treatment for 10 weeks. Furthermore, the data suggest that the higher ratio of carcinomas to papillomas observed with mezerein promotion may be a function of the lower tumor burdens obtained after promotion with this compound rather than a specific property of the chemical.
AuthorsM W Ewing, C J Conti, J L Phillips, T J Slaga, J DiGiovanni
JournalJournal of the National Cancer Institute (J Natl Cancer Inst) Vol. 81 Issue 9 Pg. 676-82 (May 03 1989) ISSN: 0027-8874 [Print] United States
PMID2496233 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Diterpenes
  • Terpenes
  • mezerein
  • 9,10-Dimethyl-1,2-benzanthracene
  • DNA
  • Tetradecanoylphorbol Acetate
Topics
  • 9,10-Dimethyl-1,2-benzanthracene
  • Animals
  • Carcinoma, Squamous Cell (chemically induced)
  • DNA (biosynthesis)
  • Diterpenes
  • Female
  • Mice
  • Papilloma (chemically induced)
  • Skin (drug effects, metabolism)
  • Skin Neoplasms (chemically induced)
  • Terpenes (toxicity)
  • Tetradecanoylphorbol Acetate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: